SUMMARY Long-term treatment with timolol in patients ages 65-75 years who survived myocardial infarction was related to a significant reduction, compared with placebo, in overall mortality (p < 0.05), total cardiac death (p < 0.01), sudden death (p < 0.05) and reinfarction (p < 0.01).
LONG-TERM /3-receptor blockade after acute myocardial infarction has been associated with a reduction in overall mortality. 1-5 However, the use of /8 blockers in elderly patients has not been carefully examined. Andersen et al. 6 found that treatment with alprenolol in patients with acute myocardial infarction increased the mortality in those older than age 65 years.
In this report, we present a detailed analysis of the Norwegian multicenter timolol trial' with respect to patients 65-75 years old compared with patients younger than 65 years old. These patients were selected retrospectively.
Methods
The study design, patient recruitment and evaluation, follow-up procedures, end-point evaluation, data handling and statistical methods have been described.'
The patients who were included were classified into three risk groups. Risk group 1 consisted of patients with recurrent myocardial infarction with or without conditions for possible high risk. Risk group 2 consisted of patients with a first myocardial infarction and one or more of five high-risk conditions. ' Group 3 consisted of low-risk patients (i.e., the remaining patients). The patients were treated with timolol (10-mg tablets) or placebo given as half a tablet twice daily for 2 days and then as one tablet twice daily.
Patients
Of the 1884 patients in the Norwegian multicenter timolol study, 732 patients (39%) were 65-75 years old; 384 were in the placebo group and 348 were in the timolol group. Before inclusion, 12.2% of the patients who met the criteria for infarction died. In the age group less than 65 years, 6.0% died, and in the age group 65-75 years, 19.6% died.
Exclusions from Entry
More patients in the age group older than 65 years (52.2%) were excluded from the study than in the age group younger than 65 years (45.6%) ( fig. 1) figure 2 . The cumulative probability of death at 33 months was 34.5% in the placebo group and 19.2% in the timolol group, a reduction of 42.5% (p = 0.03). In the younger patients, the cumulative death rate at 33 months was 14.3% in the placebo group and 9.9% in the timolol group, a reduction of 30.6% (p = 0.01). Figure 3 shows the cumulative life-table rates for sudden death in the age group above 65 years according to the principle of intention to treat. The cumulative sudden death rate at 33 months was 21.5% in the placebo group and 12.3% in the timolol group, a reduction of 42.7% (p = 0.02). In the younger patients, the cumulative sudden death rate at 33 months was 11.3% in the placebo group and 4.7% in the timolol group, a reduction of 34.0% (p = 0.02).
The sudden cardiac death rate in the timolol group compared with the placebo group was reduced by 40.4% in all patients (p < 0.001), 31% in patients 70- At baseline, the radiographic heart size was evaluated as normal, borderline or definitely enlarged. In the older age group, the mortality rate was three times higher in patients with a definitely enlarged heart than in patients with normal heart size. However, the reduction in mortality was independent of heart size ( fig. 4) major causes of in-hospital cardiac death in the older reduced incidence of both sudden death and other patients are cardiogenic shock and cardiac rupture. 7 cardiac death in the older and younger age groups After discharge from the hospital, the mortality rate (table 5) . in the timolol study was twice as high in patients older Weisfeldt9 indicated that echocardiographic indexes than 65 years of age than in patients younger than 65 of left ventricular function at rest are unchanged with years of age. The sudden death/other cardiac death age in either the presence or the absence of /3-receptor ratio was 4.7 in the younger age group and 2.9 in the blockade, but left ventricular function during exercise older age group, indicating that more patients older is reduced with age; ,3-receptor blockade might therethan 65 years of age died more than 24 hours after start fore interfere more seriously with myocardial function of symptoms, mostly from fatal reinfarction and cardiduring exercise in the older than in the younger age ac failure. However, timolol therapy was related to a group. In the timolol study, nonfatal cardiac failure (table 5) . Cardiac enlargement after myocardial infarction is a risk factor for later cardiac death.' 8 In the present study, the cardiac mortality was three times greater in patients with a definitely enlarged heart than in patients with normal heart size. However, the reduction in mortality in timolol patients was independent of baseline heart size ( fig. 4) .
Two other risk factors for later cardiac death are extensive myocardial infarction (serum aspartate aminotransferase levels exceeding four times the upper limit of normal) and transient left ventricular failure indicated by pulmonary rales.1" In these two groups, timolol treatment also reduced mortality compared with placebo. However, these results should be interpreted carefully because of the small number of patients and because the subgrouping was done retrospectively.
In the timolol study there were also fewer initial reinfarctions in the treated group than in the placebo group. The reduction was significant for the whole study (p < 0.01) and in the age group 65-75 years (p < 0.01), but not in the age group younger than 65 years (table 5) . Surprisingly, the timolol-related reduction of initial reinfarction was greatest in the age group 70-75 years. This finding may reflect the more extensive coronary artery disease in older patients, who may benefit more by a rate-dependent reduction in metabolic requirement. However, these results must also be interpreted cautiously because of the small number of patients.
This study shows a reduction in mortality and reinfarction in both younger and older patients and supports the theory that timolol's effect could be due to a major reduction in heart rate without excess heart failure or cerebral circulatory insufficiency. 
